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Abstract
Background: A full-term pregnancy has been associated with reduced risk for developing breast
cancer. In rodent models, the protective effect of pregnancy can be mimicked with a defined
regimen of estrogen and progesterone combination (E/P). However, the effects of pregnancy levels
of E/P in humans and their underlying mechanisms are not fully understood. In this report, we
investigated the growth inhibitory effects of pregnancy levels of E/P and both natural and synthetic
retinoids in an immortalized human mammary epithelial cell line, 76N TERT cell line.
Results: We observed that cell growth was modestly inhibited by E/P, 9-cis-retinoic acid (9-cis RA)
or all-trans-retinoic acid (ATRA), and strongly inhibited by N-(4-hydroxyphenyl) retinamide (HPR).
The growth inhibitory effects of retinoids were further increased in the presence of E/P, suggesting
their effects are additive. In addition, our results showed that both E/P and retinoid treatments
resulted in increased RARE and p53 gene activity. We further demonstrated that p53 and p21
protein expression were induced following the E/P and retinoid treatments. Furthermore, we
demonstrated that while the telomerase activity was moderately inhibited by E/P, 9-cis RA and
ATRA, it was almost completely abolished by HPR treatment. These inhibitions on telomerase
activity by retinoids were potentiated by co-treatment with E/P, and correlated well with their
observed growth inhibitory effects. Finally, this study provides the first evidence that estrogen
receptor beta is up-regulated in response to E/P and retinoid treatments.
Conclusion: Taken together, our studies show that part of the anti-growth effects of E/P and
retinoids is p53 dependent, and involve activation of p53  and subsequent induction of p21
expression. Inhibition of telomerase activity and up-regulation of estrogen receptor beta are also
associated with the E/P- and retinoid-mediated growth inhibition. Our studies also demonstrate
that the potency of retinoids on cell growth inhibition may be increased through combination of
estrogen and progesterone treatment.
Background
It is well documented that women who experience a full-
term pregnancy early in their lives have a significantly
reduced risk for developing breast cancer [1,2]. The
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mechanisms by which pregnancy affects maternal breast
cancer incidences are not fully understood. Previous stud-
ies suggest that the protective effect of pregnancy can be
mimicked with a defined regimen of estrogen and proges-
terone combination (E/P) in rodent models [3,4]. How-
ever, the effects of pregnancy levels of E/P in human and
their underlying mechanisms have not been investigated.
Retinoids are a promising class of chemopreventive agents
against breast cancer because of their antiproliferative and
proapoptotic properties [5,6]. Retinoic acid receptors
(RARs) and retinoid X receptors (RXRs) are nuclear tran-
scription factors that modulate the biological effects of
retinoids. Most retinoid forms, including 9-cis-retinoic
acid (9-cis RA) and all-trans-retinoic acid (ATRA), activate
RAR family members, whereas RXR family members are
activated by 9-cis RA. N-(4-hydroxyphenyl) retinamide
(HPR), a synthetic derivative of ATRA, may weakly inter-
act with retinoid receptors [7].
The 76N TERT cells were derived from a reduction mam-
moplasty specimen [8,9]. They are normal human mam-
mary epithelial cells immortalized by plasmids
containing hTERT, the human catalytic subunit of the
reverse transcriptase protein of telomerase [10]. hTERT-
expressing normal cell clones have been shown to have an
extended life span without any change in karyotype [11].
The 76N TERT cells in culture could continuously grow
about 60 population doublings [8], and the level of p53
protein has been shown to remain consistent at early or
late passages [9]. Unlike the tumor cell lines widely used
in breast cancer researches such as MCF-7 and MDA-MD-
231 cells, which have undergone several steps in tumori-
genesis, the 76N TERT cell line represents a system that is
immortal but does not yet have the capacity to form a
tumor. Hence, it is potentially a better model to study the
genetic changes, and to test the effects of carcinogenic or
chemopreventive agents on the development of mam-
mary tumors.
In this study, we investigated whether E/P induce growth
inhibition in 76N TERT cells; and the molecular mecha-
nisms by which E/P inhibited 76N TERT cell growth. For
comparison purpose, the anti-growth effect of both natu-
ral and synthetic retinoids was examined in parallel in this
immortalized mammary epithelial cell line. We also
investigated whether we could increase the responsiveness
of retinoids by using retinoids in combination with E/P.
Our studies demonstrate that 1) inhibition of cell growth
by E/P and retinoids could be partially mediated through
a p53-dependent mechanism; 2) induction of p21 expres-
sion, inhibition of telomerase activity, or up-regulation of
estrogen receptor beta (ERβ ) by E/P and retinoids may
contribute to their anti-growth effects; 3) combination of
retinoids with E/P lead to increased inhibitory effects on
cell growth.
Results
Expression of RARs, RXRs, estrogen receptors and 
progesterone receptors in 76N TERT cells
As the ability of estrogen, progesterone and retinoids to
influence cell proliferation is mediated by their respective
receptors in most cases, we first examined the expression
of these receptors in 76N TERT cells. Using Western blot
analysis, the proteins of RAR (RARα , RARβ  and RARγ ),
RXR (RXRα , RXRβ  and RXRγ ), and ER (ERα  and ERβ ) were
observed as suggested by the manufactures (Figure 1). The
antibody for the progesterone receptor (PR) detected a
protein between 85 and 125 KDa (Figure 1). The exist-
ences of RARβ  and ERβ  in 76N TERT cells were further
confirmed by quantitative RT-PCR at the mRNA level
(RARβ  data not shown, ERβ  data see Figure 6B).
Inhibition of 76N TERT cell growth by E/P and retinoids
We then tested the influence of E/P or retinoids on 76N
TERT cell growth, using [3H]thymidine incorporation
assay. The concentrations of E/P and retinoids used in the
experiments were chosen based on previous studies and
are clinically or physiologically relevant [3,4,12]. Treat-
ment of cells with E/P or all three retinoids resulted in
decreases in cell proliferation. As shown in Figure 2, treat-
ment of 76N TERT cells with 1 µM 9-cis RA or 2 µM ATRA
significantly decreased the cell growth by 28.8% and
Expression of RAR, RXR, ER and PR in 76N TERT cells Figure 1
Expression of RAR, RXR, ER and PR in 76N TERT 
cells. Whole cell lysates were analyzed by using anti-RAR, 
RXR, ER, and PR antibodies as described under "Materials 
and Methods". Blots shown are representative of 2–3 experi-
ments with similar results.
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24.5% respectively. In comparison, cells were more
responsive to HPR. Treatment with 2 µM HPR exhibit a
significant 71.4% decrease in cell growth relative to con-
trols. Combination of 1 ng/ml of β -estradiol and 1 µg/ml
of progesterone, a regime that mimics the protective
effects of pregnancy, also resulted in a significant 32.2%
decrease in cell proliferation. In the presence of E/P, the
inhibitory effects on cell growth of 9-cis RA, ATRA and
HPR were further increased to a respective 56.6%, 53.3%
and 86.8%, indicating that the anti-proliferative effect
may be additive between E/P and retinoids.
Activation of RARE and p53 gene by E/P and retinoids
Many biological responses to retinoids are thought to be
mediated through receptors by binding to retinoic acid
response elements (RAREs) and regulation of transcrip-
tional activity [5,6]. In addition, cross-talk between ER
and RAR pathways has been previously reported [13,14].
Given this, a comparison of RARE  gene activation in
response to E/P and retinoids was carried out using cells
transfected with a RARE-luciferase reporter gene construct.
As shown in Figure 3A, 76N TERT cells exhibited a respec-
tive 3.3-, 5.4-, and 2.5-fold activation of RARE gene in
response to 9-cis RA, ATRA or E/P alone. In contrast, HPR
caused no significant change in luciferase activity relative
Inhibition of 76N TERT cell growth by E/P and retinoids Figure 2
Inhibition of 76N TERT cell growth by E/P and retinoids. Cells were treated with indicated retinoids with or without E/
P for 24 hours and then labelled with [3H]thymidine as described under "Materials and Methods". Data are the means ± SE 
from 3–4 experiments. *, significant differences from control.
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Activation of RARE and p53 gene by E/P and retinoids in 76N TERT cells Figure 3
Activation of RARE and p53 gene by E/P and retinoids in 76N TERT cells. Cells were transiently transfected with the 
RARE (A) or p53 (B) reporter plasmid, and then treated with retinoids for 24 hours with or without E/P. Luciferase activity 
was measured and normalized as described under "Materials and Methods". Results are the means ± SE from 3 experiments. *, 
significant differences from control.
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to the control. In the presence of E/P, the effects of 9-cis
RA and ATRA on RARE gene activation were essentially the
same as without E/P.
Functional p53 provides a protective effect against tumor
growth [3,15]. We next examined whether E/P and retin-
oids could enhance the transcriptional activity of p53
using 76N TERT cells transfected with a p53-responsive
luciferase reporter gene construct. As shown in Figure 3B,
a 2.3-, 1.8-, 1.8- and 2.2-fold induction of luciferase activ-
ity was observed by treatment of cells with 9-cis RA, ATRA,
HPR and E/P respectively. Co-treatment with E/P and
retinoids showed no additional activation of p53 gene as
compared to their treatments alone.
Induction of p53 and p21 protein expression by E/P and 
retinoids
We then performed Western blot analysis to test whether
increased p53 gene activity is paralleled by increased p53
protein expression. Treatment with 9-cis RA, ATRA, HPR
or E/P alone slightly increased (about 1.5-fold) the expres-
sion of p53 protein. Consistent with the data on p53 gene
activation, no additive effects between E/P and retinoids
on induction of p53 protein were observed (Figure 4).
Activated p53 could induce the transcription of either p21
to cause growth arrest, or Bax to induce apoptosis [15]. We
therefore investigated whether increased p53 protein
expression can modulate the expression level of p21 or
Induction of p53 and p21 protein by E/P and retinoids in 76N TERT cells Figure 4
Induction of p53 and p21 protein by E/P and retinoids in 76N TERT cells. Cells were treated with indicated retinoids 
with or without E/P for 72 hours. Whole cell lysates were subjected to Western blot analysis using anti-p53, p21 and Bax anti-
bodies. Relative expression of each protein was determined using the same membrane, and normalized to actin protein. Data 
are fold changes compared to vehicle treatment. Blot shown is representative of 4 experiments with similar results.
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Inhibition of the telomerase activity by E/P and retinoids in 76N TERT cells Figure 5
Inhibition of the telomerase activity by E/P and retinoids in 76N TERT cells. Cells were treated with indicated retin-
oids with or without E/P for the indicated time periods. Telomerase activity was determined as described under "Materials and 
Methods". Data are the means ± SE from 2–3 measurements. *, significant differences from their own controls.
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Bax proteins in 76N TERT cells. In Figure 4, exposure to
retinoids or E/P alone did moderately increase the p21
protein level, with a 1.7-, 2.7- and 2.1-fold increase in p21
expression for ATRA, HPR and E/P respectively. The
increases of p21 protein expression with combined E/P
and retinoids were similar to that observed when E/P and
retinoids were used alone. In addition, no significant
effects by E/P or retinoids on Bax protein expression were
observed in 76N TERT cells.
Inhibition of telomerase activity by E/P and retinoids
Activation of telomerase is an early event in the develop-
ment of breast cancers that may lead to cellular immortal-
ity, a critical and rate-limiting step in oncogenesis [16,17].
Activated p53 has been associated with regulation of the
telomerase activity [18-20]. To evaluate the effects of E/P
and retinoids on telomerase activity in 76N TERT cells,
cells were treated for different time periods with E/P and
retinoids, and the levels of telomerase activity were deter-
mined by a quantitative real-time PCR method. As shown
in Figure 5, treatment with E/P decreased telomerase activ-
ity in a time-dependent manner with a 63.3% inhibition
at 72 hours, whereas vehicle treatment had no effect at any
time during the experiment. The maximum inhibition on
telomerase activity was observed at 24 hours for both 9-cis
RA and ATRA treatments, with a respective of 68.9% and
69.4% decrease. In comparison, the effects of HPR
occurred more rapidly, with a complete inhibition at 16
hours, and persisted throughout the treatment. The inhib-
itory effects of 9-cis RA, ATRA or HPR and E/P seemed to
be additive, as in the presence of E/P, 9-cis RA, ATRA or
HPR showed increased inhibitions at various time points.
These effects correlate well with their observed growth
inhibitory effects in 76N TERT cells, suggesting that inhi-
bition of telomerase activity by E/P and retinoids may
contribute to their additive effects on inhibition of cell
growth.
Induction of ERβ  expression by E/P and retinoids
There is growing evidence that ERβ  could be an inhibitor
of tumorigenesis of breast cancer [21-23]. We examined
whether there were any changes in the expression of ERβ
in response to E/P and retinoid treatment in 76N TERT
cells. After treatment of cells with retinoids or E/P for 72
hours, the amount of ERβ  protein was determined by
Western blot analysis. As shown in Figure 6A, the normal-
ized ERβ  protein showed a respective 2.1-, 2.3-, and 1.5-
fold increase in response to ATRA, HPR and E/P, as com-
pared to the vehicle treatment.
We also carried out a quantitative analysis of ERβ  mRNA
expression in response to E/P and retinoid treatment in
76N TERT cells using a real-time PCR assay. As shown in
Figure 6B, there was a 2.0-, 2.3- or 2.8-fold induction of
ERβ  mRNA levels in HPR, E/P or combination of HPR and
E/P treated cells, respectively.
Discussion
Similar to retinoids, a full-term pregnancy has been asso-
ciated with beneficial effects on breast cancer risk over the
long term [1,2]. The mechanisms by which pregnancy
affects maternal breast cancer incidences are not fully
understood. Studies have showed that higher concentra-
tions of progesterone elicit a growth-inhibiting response
from normal and cancerous breast cells [24,25], and are
inversely related to breast cancer incidence [26]. In this
study, we examined the ability of pregnancy levels of E/P
and retinoids to affect the growth of the immortalized
normal mammary epithelial cells. Our results demon-
strated that three isoforms for RAR and RXR (α , β , γ ), two
isoforms for ER (α  and β ), and PR receptor proteins are
expressed by 76N TERT cells. Treatment with 9-cis RA,
ATRA, HPR or E/P inhibited 76N TERT cell proliferation
and resulted in the activation of p53 gene, followed by
increased expression of p53 protein and p21 protein, and
inhibition of telomerase activity. Additionally, we first
report here that the expression of ERβ  is induced in
response to E/P and retinoid treatment at both the tran-
scriptional and translational levels. Importantly, we dem-
onstrate that the inhibitory effects of retinoids on cell
growth are more effective in the presence of E/P, and cor-
relate well with their inhibitory effects on telomerase
activity in 76N TERT cells.
Our data suggest that the growth inhibitory effects of E/P
and retinoids may involve the activation of p53 pathway
in 76N TERT cells. First, our results showed that both E/P
and retinoid treatments lead to the increased p53 gene
activity. Secondly, we demonstrated that the protein
expression of p53 and p21 were increased following the
treatment. It has been shown that p21 can inhibit cyclin
A/cdk2 kinase activity and subsequently result in cell cycle
arrest [27,28]. Our data is in line with the previous find-
ings that in normal mammary epithelial cells, retinoids
induce cell cycle arrest which is associated with an
increase in p21 expression [29]; and that in both rats and
mice, p53 is activated in response to E/P and this activa-
tion is sustained to induce p21 [3]. Thirdly, our data
showed that treatment with E/P or retinoids decreased the
telomerase activity in 76N TERT cells. Although a few
reports suggest that telomerase activity appears to be inde-
pendent of p53  expression or mutation [30,31], the
majority of the evidence to date support the involvement
of p53 in regulation of telomerase activity in mammary
epithelial cells and breast cancer [18-20]. The molecular
mechanisms of regulation of telomerase activity by p53
may involve down-regulation of hTERT transcription or
the interaction of p53  with other transcription factors
[19].Cancer Cell International 2005, 5:6 http://www.cancerci.com/content/5/1/6
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Induction of ERβ  expression by E/P and retinoids in 76N TERT cells Figure 6
Induction of ERβ  expression by E/P and retinoids in 76N TERT cells. Cells were treated with indicated retinoids with 
or without E/P for 72 hours. A. Western blot analysis of ERβ  protein. Relative ERβ  expression was normalized to actin protein 
and expressed as fold changes compared to vehicle treatment. Blot shown is representative of 3 experiments with similar 
results. B. Quantitative RT-PCR analysis of ERβ  genes. Data are the means ± SE from 3 experiments. *, significant differences 
from their own controls.
Treatment
ERβ β β β
Actin
1.0 1.1 2.1 2.3 1.5 1.9 2.0 1.6
Vehicle
9-cis
RA
ATRA
HPR
E/P
E/P+ATRA
E/P+HPR
E/P+9-cis
RA
A
B
0
5
10
15
20
25
Vehicle
9-cis RA
ATRA
HPR
E/P
E/P+9-cis RA
E/P+ATRA
E/P+HPR
F
o
l
d
m
R
N
A
L
e
v
e
l
* * *Cancer Cell International 2005, 5:6 http://www.cancerci.com/content/5/1/6
Page 9 of 12
(page number not for citation purposes)
However, our data also suggest the possibility that inhibi-
tion of cell growth by E/P and retinoids may be
independent of p53 pathway in 76N TERT cells. Our data
show that the enhancing effects of retinoids on p53 gene
activation or on the p53 and p21 protein expression were
not further augmented by the addition of E/P, unlike their
inhibitory effects on cell growth, indicating that other
mechanisms besides the p53 pathway are likely to be
involved. A p53-independent cell cycle arrest by retinoids
has been previously suggested in a number of breast carci-
noma cells [27,32]. The p53-independent inhibitory
effects of retinoids on cell growth can be exerted through
various mechanisms including regulation of other genes
that play critical roles in cell cycle progression such as c-
myc [18], inhibition of activator protein mediated tran-
scription [33], or induction of caspase-independent cell
death via calcium and calpain [34]. However, the mecha-
nisms of E/P-mediated p53-independent cell growth inhi-
bition are still unknown, and are currently under
investigation using cell lines with different functional p53
systems.
Clearly, our data suggest that there are some overlaps
between E/P- and retinoid-mediated growth inhibition in
76N TERT cells, considering that in response to E/P and
retinoid treatments, same effectors such as RARE and p53
gene, p53 and p21 protein, and the telomerase activity
were affected. Additionally, there also seems to be cross-
talk between the E/P- and retinoid-mediated growth inhi-
bition. Previous studies have suggested that there is cross-
talk between ERβ  and RAR pathways [13,14,35]. Here, we
demonstrated that the RARE gene activity was increased in
response to E/P treatment. Furthermore, for the first time,
we showed that treatment of immortal cells with E/P or
retinoids could induce the expression of ERβ , both at the
mRNA and protein level. The expression of ERβ  often is
found to be decreased markedly in the early stages of
mammary carcinogenesis [22]. Loss of ERβ  expression has
been suggested as one of the events leading to the devel-
opment of breast cancer [36]. Our data may reveal
another important mechanism by which E/P and retin-
oids produce their anticancer function, indicating ERβ
may represent a possible therapeutic target in breast can-
cer prevention.
More importantly, our data show that the growth-inhibi-
tory effects of retinoids were potentiated by co-treatment
with E/P in 76N TERT cells. These observations indicate
that different mechanisms may be involved in E/P- and
retinoid-mediated inhibition of cell growth. Our results of
their differential inhibitory effects on telomerase activity
may provide some explanation for this. Although E/P and
all three retinoids inhibited telomerase activity, the time
courses of their actions were different. While retinoids
produced their maximal inhibitory effects around 16 to
24 hours after treatment, E/P required 72 hours to reach
its maximal inhibition, suggesting different mediators
may be utilized to decrease telomerase activity by E/P and
retinoids. ATRA and 9-cis RA have been previously
reported to inhibit cell growth and decrease telomerase
activity through down-regulation of the expression of
hTERT telomerase gene [37]. On the other hand, proges-
terone treatment has been shown to down-regulate telom-
erase activity by modulation of cell cycle phases [38].
Previous studies have also provided evidence that the
function of p53 in suppression of telomerase activity is
separable from its cell cycle checkpoint function [20].
Therefore, it is likely that even though E/P and retinoids
treatments both activate p53 pathway, they may use dif-
ferent mechanisms to inhibit telomerase activity. The dif-
ferent mediators involved in the inhibitory effects of E/P
and retinoids on telomerase activity may contribute to
their additive effects on inhibition of 76N TERT cell
growth. The detailed mediator mechanisms down-stream
of p53 and up-stream of telomerase activity for both E/P
and retinoid pathways remain to be defined.
Several lines of evidence suggest that the mechanisms
through which HPR regulates cell growth seem different
than those by 9-cis RA and ATRA in 76N TERT cells. In the
[3H]thymidine incorporation experiments, our results
showed that whereas only 25–30% inhibition was
observed for 9-cis RA and ATRA, 70% inhibition was
reached by HPR. In addition, in the RARE-luciferase activ-
ity assay, 9-cis RA and ATRA induce about 3- to 5-fold acti-
vation on RARE gene activity. In contrast, HPR treatment
resulted in no significant change. Finally, our data showed
that 9-cis RA or ATRA treatment caused a moderate inhib-
itory effect on telomerase activity. In comparison, the tel-
omerase activity is almost completely abolished by HPR
treatment. The time courses of their inhibition of telomer-
ase activity were different as well. While 9-cis RA and
ATRA maximally inhibited the telomerase activity around
24 hours after treatment, HPR produced its maximal effect
at 16 hours post-treatment. An obvious explanation for
these different responses observed between 9-cis RA,
ATRA and HPR is that these retinoids most likely possess
different mechanisms for their actions. As suggested by
numerous investigators, 9-cis RA and ATRA may function
through the classical retinoid pathways involving the
RARs and RXRs. On the other hand, in addition to
activation the retinoid receptors [7a], HPR may also func-
tion through alternative pathways such as down-regula-
tion of the IGF system [39], activation of TGF-beta [40],
induction of genes which have antiproliferative activity
[41], inhibition of aromatase activity and expression [42],
and involvement of cellular signals such as reactive oxy-
gen species [43] and the sphingolipid ceramide [44].Cancer Cell International 2005, 5:6 http://www.cancerci.com/content/5/1/6
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Conclusion
In summary, our data demonstrate that 76N TERT cells
express RAR, RXR, ER and PR, and represent a potential
useful model to investigate the genetic changes, and the
carcinogenic or chemopreventive effects of new agents on
the development of mammary tumors. In addition, our
data clearly suggest that part of the anti-growth effects of
E/P is mediated through a p53-dependent pathway, as
well as the involvement of the inhibition of telomerase
activity and induction of ERβ . Comparing the E/P- and
retinoid-mediated inhibitory effects on cell growth, there
are overlaps, cross-talks and distinct effectors between
these pathways. Furthermore, our studies suggest that
retinoids may be more effective when combined with E/P
to prevent breast cancer development. This increased
potency and sensitized response to retinoids with com-
bined E/P treatment might have several important clinical
implications for anti-cancer agents that mimic E/P effects.
Firstly, it might allow the currently used RA regimens to
show improved response in cancer prevention. Secondly,
it may be sufficient to overcome some acquired or intrin-
sic RA resistance in cancer cells. Finally, it may lower the
required does of either classes of anticancer agents used,
leading to less side effects or toxicity. Overall, our studies
better the understandings of the common and the unique
mechanisms by which E/P and retinoids regulate cell
growth, and may help us to design or to improve the clin-
ical applications of anti-cancer agents.
Methods
Chemicals
ATRA, 9-cis RA, HPR, β -estradiol and progesterone were
all purchased from Sigma (St. Louis, MO, USA) and
dissolved in ethanol. The final concentration was 2 µM for
ATRA and HPR, 1 µM for 9-cis RA, 1 ng/ml for β -estradiol
and 1 µg/ml for progesterone. These concentrations were
chosen based on previous studies and are clinically or
physiologically relevant [3,4,12].
Culture of 76N TERT cells
Cell line was originally supplied and cultured as described
by Band et al. [8]. The culture medium D-MEM/F-12, fetal
bovine serum, penicillin, streptomycin, and gentamicin
were from Gibco (Carlsbad, CA, USA). All the other cell
culture reagents were from Sigma (St. Louis, MO, USA).
Cells were grown in D-MEM/F-12 mixture (1:1, vol/vol)
containing 15 mM HEPES buffer and 2.5 mM L-
glutamine, supplemented with 1% fetal bovine serum,
12.5 ng/ml epidermal growth factor, 10 nM triiodothyro-
nine, 50 µM freshly made ascorbic acid, 2 nM estradiol, 1
µg/ml insulin, 2.8 µM hydrocortisone, 0.1 mM eth-
anolamine, 0.1 mM phosphorylethanolamine, 10 µg/ml
transferrin, 15 nM selenite, 1 ng/ml cholera toxin, 35 µg/
ml bovine pituitary extract, 100 units/ml penicillin, 100
mg/ml streptomycin, and 20 µg/ml gentamicin. Cells
were maintained in 95% humidified air plus 5% CO2 and
sub-cultured weekly. All experiments were performed on
cells with passage numbers from 6 to 15.
[3H]Thymidine Incorporation Assay
Cells were seeded into 24-well plates at 5 × 104 cells per
well and incubated at 37°C overnight. Cells were then
treated in triplicates with indicated retinoids in the pres-
ence or absence of E/P for 24 hours. After labelling cells
with 1 µCi/ml of [3H]thymidine (Amersham, Arlington
Heights, IL, USA) for 24 hours, cells were harvested by
washing with PBS and 10% TCA, solubilizing with the
mixture of 0.1% SDS and 0.1N NaOH. Aliquots were
taken for the quantification of radioactivity by the Tri-
Carb 2900 TR Liquid Scintillation Analyzer (Perkin Elmer,
Wellesley, MA, USA). Incorporation of [3H]thymidine
was expressed as a fold change from vehicle control under
the same conditions.
Luciferase Reporter Assays
Cells were seeded in 24-well plates at 5 × 104 cells per well.
Cells were transiently transfected with 0.5 µg of either a
RARE-luciferase or a p53-luciferase plasmid along with
0.05 µg of pCMV-Renilla luciferase using the SuperFect
transfection reagent (QIAGEN, Valencia, CA, USA), fol-
lowing the manufacturer's recommended procedure.
Twenty-four hours after transfection, triplicate cultures
were treated with retinoids for 24 h in the presence or
absence of E/P. The cells were then washed and lysed. The
luciferase activities were measured using the DUAL-luci-
ferase Assay System (Promega, Madison, WI, USA), and
normalized by pCMV-Renilla luciferase activity for each
sample.
Real-Time PCR Telomerase Activity Assay
Cells were lysed in CHAPS lysis buffer (Chemicon Inter-
national, Temecula, CA, USA) and incubated at 4°C for
30 min. The lysate was then centrifuged at 12000 × g for
20 min at 4°C, and the supernatant was collected. The
protein concentration was measured in each extract using
the BCA protein Assay Reagent Kit (Pierce, Rockford, IL,
USA). Telomerase activity was determined in duplicates
by a quantitative real-time PCR telomerase detection Kit
(Allied Biotech, Ijamsville, MD, USA) according to the
manufacturer's protocol, using Mx4000 Multiplex Quan-
titative PCR System (Stratagene, La Jolla, CA, USA).
Quantitative RT-PCR for ERβ  gene analysis
Cells at subconfluence were treated with retinoids in the
presence or absence of E/P for 72 hours. Total RNA was
extracted with TRIZOL Reagent from Gibco (Carlsbad,
CA, USA) according to the instructions of the manufac-
ture. Single-stranded cDNA was made from 1 µg of total
RNA with the Cells-to-cDNA kit (Ambion, Inc., Austin,
TX, USA) at 42°C for 15 min. The primers for ERβ  wereCancer Cell International 2005, 5:6 http://www.cancerci.com/content/5/1/6
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5'CGA TGC TTT GGT TTG GGT GAT 3' (forward) and
5'GCC CTC TTT GCT TTT ACT GTC 3' (reverse). The prim-
ers for GAPDH were 5'CCA TGG AGA AGG CTG GGG 3'
(forward) and 5'CAA AGT TGT CAT GGA TGA CC 3'
(reverse). All primers were from Integrated DNA Technol-
ogies, Inc. (Coralville, IA, USA). cDNA (1 µl) was ampli-
fied in duplicates in Mx4000 Multiplex Quantitative PCR
System (Stratagene, La Jolla, CA, USA) by using Brilliant
SYBR Green QPCR Master Mix from Stratagene (La Jolla,
CA, USA). The reaction was carried out at 95°C for 10 min
to denature, 40 cycles of 95°C for 30 sec, 55°C for 60 sec,
72°C for 60 sec. ERβ  gene was quantified and normalized
with external standard GAPDH.
Western blot analysis
Cells were treated with retinoids in the presence or
absence of E/P for 72 hours. Cell lysates were obtained by
incubating cells for 30 minutes at 4°C in a buffer contain-
ing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5% NP40,
100 mM NaF, 10 mM MgCl2, and protease inhibitor cock-
tail (Sigma, St. Louis, MO, USA), followed by centrifuged
at 12,000 rpm for 20 min. Protein content was deter-
mined using the BCA Protein Assay Reagent Kit (Pierce,
Rockford, IL, USA). Cell lysates (~30 µg protein) were sep-
arated on 10% polyacrylamide gels in the presence of
0.1% SDS with prestained low-range molecular-weight
standards (Biorad, Richmond, CA, USA). After transfer,
the membranes were blocked and then probed with anti-
bodies against interested proteins as suggested by
manufactures, followed by incubation with a peroxidase-
conjugated secondary antibody. Immunoreactive bands
were developed with an ECL reagent from Amersham
(Arlington Heights, Il, USA). All blots were probed with
anti-actin to normalize for loading differences.
Quantification of gels was carried out using ImageJ soft-
ware (NIH, Bethesda, Maryland, USA).
The p53 (DO-1), p21 (F-5) and RARγ  (G-1) mouse mon-
oclonal antibodies, and RXRα  (D-20) polyclonal
antibody were from Santa Cruz Biotechnology Inc (Santa
Cruz, CA, USA). Anti-ERβ  (Ab-2), ER (Ab-1), PR (Ab-1),
RARα  and RARβ  mouse monoclonal antibodies, and Bax
(Ab-1) polyclonal antibody were from Calbiochem (San
Diego, CA, USA). Monoclonal anti-actin, RXRβ  and RXRγ
were from Sigma (St Louis, MO, USA).
Statistical Analysis
Statistical differences were analyzed by T-test. Levels of
statistical significance were set at p < 0.05.
List of abbreviations
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